LLNL Awarded $2.5M to Move Pathogen Detection Tests to NanoString Platform
June 07, 2011
LLNL Awarded $2.5M to Move Pathogen Detection Tests to NanoString Platform
The project aims to develop high-content, multiplex assays capable of simultaneously detecting 35 National Institute of Allergy and Infectious Diseases category A, B, and C viral agents, plus quantifying cytokine and chemokine responses in patients.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NanoString Technologies Files to Go Public
May 20, 2013 / GenomeWeb Daily News - IP Roundup: NanoString Technologies, TNO, Roche NimbleGen, Quanterix, HistoRx
April 9, 2013 / BioArray News - New Products: NanoString's Single Cell Gene Expression Application, Genalyte's Custom Spotting Service, InDevr's Custom Arrays
September 25, 2012 / BioArray News - People in the News: Brynn Levy, Dale Levitzke, Stefan Gluck
August 14, 2012 / BioArray News - NanoString Establishes Dx Unit as Breast Cancer Test Moves Closer to FDA Submission
May 29, 2012 / BioArray News